People: Sagent Pharmaceuticals Inc (SGNT.O)

SGNT.O on Nasdaq

26.55USD
21 Aug 2014
Price Change (% chg)

$0.19 (+0.72%)
Prev Close
$26.36
Open
$26.27
Day's High
$26.68
Day's Low
$26.15
Volume
130,928
Avg. Vol
236,757
52-wk High
$27.57
52-wk Low
$17.49

Search Stocks

Summary

Name Age Since Current Position

Jeffrey Yordon

65 2013 Chairman of the Board, Chief Executive Officer

James Hussey

55 2013 President

Jonathon Singer

50 2012 Chief Financial Officer, Executive Vice President

Michael Logerfo

49 2012 Executive Vice President, Chief Legal Officer, Corporate Secretary

Albert Patterson

70 2012 Executive Vice President - National Accounts and Corporate Development

Jeffrey Greve

39 2011 Vice President, Controller

Lorin Drake

61 2012 Corporate Vice President - Sales

Robert Flanagan

57 2012 Lead Independent Director

Mary Behrens

53 2010 Independent Director

Michael Fekete

49 2013 Independent Director

Anthony Krizman

57 2010 Independent Director

Frank Kung

65 2006 Independent Director

Biographies

Name Description

Jeffrey Yordon

Mr. Jeffrey M. Yordon is Chairman of the Board, Chief Executive Officerof Sagent Pharmaceuticals, Inc. He has served as our Chief Executive Officer and chairman of our Board since March 2013, and served as our President, Chief Executive Officer and chairman of our Board from April 2006 through March 2013. Prior to joining our company, from February 1996 to March 2006, Mr. Yordon held the positions of Chief Strategic Officer, Co-Chief Operating Officer and President of American Pharmaceutical Partners (now known as Abraxis Pharmaceutical Products) and was a member of its board of directors. Prior to that, Mr. Yordon held the positions of President of Faulding Pharmaceuticals plc; Executive Vice President of Gensia Laboratories; President and Chief Executive Officer of YorPharm and Executive Vice President and President of LyphoMed, Inc. Mr. Yordon served as chairman of the board of directors of Pharmaceutical Partners of Canada and Drug Source Company and member of the board of directors of the Drug, Chemical & Associated Technologies Association. Mr. Yordon received a BA from Northern Illinois University.

James Hussey

Mr. James M. Hussey serves as President of Sagent Pharmaceuticals, Inc., effective March 25, 2013. Prior to joining company, Mr. Hussey served as Chief Executive Officer of NanoInk, a privately held Nanolithography company, from January 2008 through March 2013. Prior to joining NanoInk, Mr. Hussey was Vice President, Strategic Planning at Ovation Pharmaceuticals, which he joined in June 2005. Prior to that, Mr. Hussey worked for NeoPharm, Inc., Physicians Quality Care, Inc., and the Bristol-Myers Squibb Company. Mr. Hussey earned a BS in pharmacy from Butler University and an MBA from the University of Illinois at Chicago.

Jonathon Singer

Mr. Jonathon M. Singer is Chief Financial Officer, Executive Vice President of Sagent Pharmaceuticals Inc. He has served as our Chief Financial Officer since September 2011, and was appointed Executive Vice President and Chief Financial Officer in March 2012. Prior to joining our company, from October 2006 to September 2011, Mr. Singer served as Senior Vice President, Treasurer, Secretary and Chief Financial Officer of Landauer, Inc. Prior to joining Landauer, Mr. Singer was Vice President of Global Finance, Chief Financial Officer of the Medical Segment, for Teleflex, Inc., which he joined in 2004. Prior to that, Mr. Singer worked for Cardinal Health Inc., R.R. Donnelly & Sons Company and KPMG LLP. Mr. Singer served as a certified public accountant licensed in Ohio, and received a BS in business administration from Miami University in Ohio and an MA in management from Northwestern University’s Kellogg Graduate School of Management.

Michael Logerfo

Mr. Michael Logerfo is Executive Vice President, Chief Legal Officer, Corporate Secretary of Sagent Pharmaceuticals Inc., since March 2012. Prior to that, Mr. Logerfo had served as Corporate Vice President since March 2007, our Chief Legal Officer since April 2010, and our Secretary since September 2010. From March 2007 to August 2008, Mr. Logerfo served as Chief Operating Officer of our KSCP joint venture. From October 1999 to January 2006, Mr. Logerfo held the positions of President and Chief Executive Officer of Flavine Holding Co. and its affiliates, a privately held group engaged in the development and sale of active pharmaceutical ingredients. Mr. Logerfo has been a lawyer in private practice, from September 2006 to January 2007, as a partner with the law firm Phillips Nizer, and from June 1990 to October 1999, as a member of the firm Ferro Labella Logerfo & Zucker, PC and its predecessors and successors. He is admitted to practice law in New Jersey and New York. Mr. Logerfo received a BA in Government and a JD from Georgetown University.

Albert Patterson

Mr. Albert Patterson, is Executive Vice President - National Accounts and Corporate Development of Sagent Pharmaceuticals Inc. Mr. Patterson served as Executive Vice President, Operations, from March 2012 through August 2012, and as Senior Vice President, Operations from June 2010 through March 2012. Prior to joining company, from September 2004 to June 2010, Mr. Patterson held the position of Chief Executive Officer of The Bert Patterson Group, a healthcare consulting company focused on the generic pharmaceutical industry. Prior to that, from July 2003 to August 2004, Mr. Patterson held the positions of President and Chief Executive Officer of Excel Rx GSO, a group service organization concentrating on the alternate site healthcare sector. From July 1997 through July 2003, Mr. Patterson held the positions of Vice President of Pharmacy, Vice President of the Contract Center of Excellence and Vice President of Alternate Site Healthcare and Business Development of Premier, Inc., a national healthcare Group Purchasing Organization. From February 1988 through June 1997, Mr. Patterson held the positions of Director of Hospital Pharmacy, Director of the Office of Drug Product Management and internal Pharmacy Benefit Manager of the U.S. Department of Veterans Affairs. Mr. Patterson served as a member of the board of directors of the Ronald McDonald House near Loyola University Medical Center. Mr. Patterson has also served in faculty positions at Illinois, Wisconsin and Purdue Colleges of Pharmacy and as a member of the Dean’s committee at Midwestern University, Chicago College of Pharmacy. Mr. Patterson received a BS in Pharmacy from the University of Illinois College of Pharmacy.

Jeffrey Greve

Mr. Jeffrey Greve, CPA, is Vice President, Controller of Sagent Pharmaceuticals, Inc., since October 2011. Mr. Greve joined the Company in February 2011 as our Director, External and Technical Reporting. Prior to joining Sagent, Mr. Greve was a Senior Manager in the Assurance practice of PricewaterhouseCoopers LLP, which he initially joined as a Staff Accountant in 1996. Mr. Greve received a BBA with a concentration in accountancy from the University of Notre Dame and is a Certified Public Accountant.

Lorin Drake

Mr. Lorin Drake is Corporate Vice President - Sales of Sagent Pharmaceuticals Inc, Mr. Drake served as Corporate Vice President, Sales and Marketing, from March 2012 through August 2012, and as our Vice President, Sales and Marketing from May 2006 through March 2012. Prior to joining our company, from 1998 to May 2006, Mr. Drake held the positions of Senior Director of Sales and Vice President of Sales of American Pharmaceutical Partners. Prior to that Mr. Drake held various sales related positions at Fujisawa USA and Lyphomed. Mr. Drake received a BS in Economics from Manchester College.

Robert Flanagan

Mr. Robert J. Flanagan is Lead Independent Director of Sagent Pharmaceuticals Inc. Mr. Flanagan has held the position of Executive Vice President of Clark Enterprises, Inc. since 1989, overseeing the acquisition, management and development of new investment opportunities. Prior to that, Mr. Flanagan served as the treasurer, secretary and a member of the board of directors of Baltimore Orioles, Inc. Mr. Flanagan has also served on the board of directors of Martek Biosciences Corporation, where he served as Chairman, and Castle Brands, Inc. and is a Certified Public Accountant licensed in Washington, D.C. As a result of these and other professional experiences, we believe Mr. Flanagan possesses knowledge and experience in accounting, finance and capital structure; strategic planning and leadership of complex organizations; people management; board governance; and board practices of other entities that strengthen the Board’s collective qualifications, skills and experience. Mr. Flanagan received a BS in Business Administration from Georgetown University and an MST from the American University School of Business.

Mary Behrens

Ms. Mary Taylor Behrens is Independent Director of Sagent Pharmaceuticals Inc., since November 2010. s. Behrens has been engaged in private consulting since February 2003 and has held the position of President of Newfane Advisors, Inc., a consulting firm, since November 2004. Prior to that, from February 2001 until January 2003, Ms. Behrens served as Head or Co-Head of Merrill Lynch Investment Managers, Americas Region. From February 1998 until January 2001, Ms. Behrens was a Senior Vice President of Merrill Lynch & Co., serving as Head of Human Resources and a member of its Executive Committee. Ms. Behrens served as a member of the board of directors of Manor Care, Inc. from November 2004 until it went private in December 2007. As a result of these and other professional experiences, Ms. Behrens holds a BA in Government from Georgetown University.

Michael Fekete

Mr. Michael Fekete serves as Independent Director of Sagent Pharmaceuticals, Inc., effective July 10, 2013. Mr. Fekete has served as an independent corporate advisor specializing in capital markets, mergers and acquisitions and general corporate strategy since 2009. From 2005 through 2009, Mr. Fekete served as the Managing Director, Head of West Coast Healthcare Investment Banking for Wells Fargo / Wachovia Securities. Prior to that, Mr. Fekete worked in investment banking at CIBC World Markets, Oppenheimer & Co., Inc., and L.F. Rothschild & Co., Inc. Mr. Fekete is a director of DFB Pharmaceuticals, a privately held specialty pharmaceutical company, and of Symetis SA, a privately held company developing minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. As a result of these and other professional experiences, we believe Mr. Fekete possesses knowledge and experience in finance and capital structure; strategic planning; the evaluation of strategic opportunities; and board practices of other entities that strengthen the Board’s collective qualifications, skills and experience. Mr. Fekete earned a BS in business administration from the Pennsylvania State University.

Anthony Krizman

Mr. Anthony Krizman is Independent Director of Sagent Pharmaceuticals Inc., since July 2010. Mr. Krizman has served as the Chairman of Drake House Capital LLC, a private investment firm, since July 2012. Prior to that, Mr. Krizman held the position of Assurance Partner at PricewaterhouseCoopers, LLP (“PwC”) through June 30, 2010, when he retired. In addition, his responsibilities at PwC included Midwest Region Risk Management Leader, PwC Assurance Quality Board Member and Managing Partner, Northwest Ohio Practice. During his 32-year tenure at PwC, Mr. Krizman advised his clients on a substantial number of issues including: preparation for and execution of private placements and initial public offerings, implementation of Sarbanes-Oxley reporting requirements, and due diligence relating to major acquisitions and carve-outs of business units in divestitures. Mr. Krizman has extensive experience in managing annual financial statements and internal control audits, as well as strategic special projects for companies in the healthcare, consumer packaged goods, automotive and service industries. Mr. Krizman is a Certified Public Accountant. As a result of these and other professional experiences, we believe Mr. Krizman possesses knowledge and experience in accounting, finance and capital structure; strategic planning and leadership of complex organizations; people management; and board practices of other entities that strengthen the Board’s collective qualifications, skills and experience. Mr. Krizman received a BS in Accounting and an MBA from Indiana University.

Frank Kung

Dr. Frank F. Kung, Ph.D., is Independent Director of Sagent Pharmaceuticals Inc., since May 2006. Dr. Kung is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments) and has been the managing partner since February 1997. Prior to that, Dr. Kung held the positions of co-founder, Chairman and Chief Executive Officer of Genelabs Technologies, Inc.; and co-founder of Cetus Immune Corporation (later acquired by its parent company, Cetus Corporation). Dr. Kung has served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; the Asian American Manufacturing Association; and Nanjing King-friend Biochemical Pharmaceutical Co. He was also appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. As a result of these and other professional experiences, Dr. Kung received a BS in Chemistry from the National Tsing Hua University in Taiwan and a Ph.D. in Molecular Biology and an MBA from the University of California at Berkeley.

Basic Compensation

Name Fiscal Year Total

Jeffrey Yordon

1,768,940

James Hussey

1,529,590

Jonathon Singer

732,156

Michael Logerfo

709,536

Albert Patterson

681,745

Jeffrey Greve

--

Lorin Drake

290,957

Robert Flanagan

--

Mary Behrens

--

Michael Fekete

--

Anthony Krizman

--

Frank Kung

--
As Of 30 Dec 2013

Options Compensation

Search Stocks